Development of in vitro peptide substrates for human rhinovirus-14 2A protease

被引:12
作者
Wang, QM [1 ]
Johnson, RB
Sommergruber, W
Shepherd, TA
机构
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Boehringer Ingelheim Res Vienna, A-1121 Vienna, Austria
[3] Bender & Co, A-1121 Vienna, Austria
关键词
D O I
10.1006/abbi.1998.0746
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purified 2A protease from human rhinovirus serotype-14 (HRV14) was unable to efficiently cleave a 16-mer peptide representing its authentic cis-cleavage site on the viral polyprotein, implying that in vivo cis cleavage by this enzyme might be very different from its in vitro trans activity. Presence of a serine at position P2 and a leucine at P2' in the 16-mer peptide was found to be responsible for the low peptide cleavage efficiency. To search for an efficient peptide substrate for HRV14 2A, small peptides derived from other rhinovirus 2A protease cleavage sites were synthesized and tested. These results suggested that the N-terminal 8 amino acids were sufficient for HRV14 2A cleavage to occur, although the P1' and P2' residue identities were important to the cleavage of peptides with amino acids occupying both sides of the scissile bond. On the basis of the 2A substrate requirements, a sensitive fluorometric assay for the viral 2A proteases was developed using peptides with anthranilide and 3-nitrotyrosine as the resonance energy transfer donor/quencher pair. Our data indicated that these fluorescent peptide substrates were suitable for 2A protease characterization and inhibitor evaluation. (C) 1998 Academic Press.
引用
收藏
页码:12 / 18
页数:7
相关论文
共 32 条
[1]   MANY RHINOVIRUS SEROTYPES SHARE THE SAME CELLULAR RECEPTOR [J].
ABRAHAM, G ;
COLONNO, RJ .
JOURNAL OF VIROLOGY, 1984, 51 (02) :340-345
[2]   2 GROUPS OF RHINOVIRUSES REVEALED BY A PANEL OF ANTIVIRAL COMPOUNDS PRESENT SEQUENCE DIVERGENCE AND DIFFERENTIAL PATHOGENICITY [J].
ANDRIES, K ;
DEWINDT, B ;
SNOEKS, J ;
WOUTERS, L ;
MOEREELS, H ;
LEWI, PJ ;
JANSSEN, PAJ .
JOURNAL OF VIROLOGY, 1990, 64 (03) :1117-1123
[3]   PURIFICATION OF RECOMBINANT HUMAN RHINOVIRUS-14-3C PROTEASE EXPRESSED IN ESCHERICHIA-COLI [J].
BIRCH, GM ;
BLACK, T ;
MALCOLM, SK ;
LAI, MT ;
ZIMMERMAN, RE ;
JASKUNAS, SR .
PROTEIN EXPRESSION AND PURIFICATION, 1995, 6 (05) :609-618
[4]  
CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062
[5]  
COUCH RB, 1990, VIROLOGY, P607
[6]   CYSTEINE PROTEASES OF POSITIVE STRAND RNA VIRUSES AND CHYMOTRYPSIN-LIKE SERINE PROTEASES - A DISTINCT PROTEIN SUPERFAMILY WITH A COMMON STRUCTURAL FOLD [J].
GORBALENYA, AE ;
DONCHENKO, AP ;
BLINOV, VM ;
KOONIN, EV .
FEBS LETTERS, 1989, 243 (02) :103-114
[7]   CHARACTERIZATION OF POLIOVIRUS-2A PROTEINASE BY MUTATIONAL ANALYSIS - RESIDUES REQUIRED FOR AUTOCATALYTIC ACTIVITY ARE ESSENTIAL FOR INDUCTION OF CLEAVAGE OF EUKARYOTIC INITIATION FACTOR-4F POLYPEPTIDE P220 [J].
HELLEN, CUT ;
FACKE, M ;
KRAUSSLICH, HG ;
LEE, CK ;
WIMMER, E .
JOURNAL OF VIROLOGY, 1991, 65 (08) :4226-4231
[8]   MOLECULAR RELATIONSHIPS BETWEEN 21 HUMAN RHINOVIRUS SEROTYPES [J].
HORSNELL, C ;
GAMA, RE ;
HUGHES, PJ ;
STANWAY, G .
JOURNAL OF GENERAL VIROLOGY, 1995, 76 :2549-2555
[9]   Inhibition of human rhinovirus 3C protease by homophthalimides [J].
Jungheim, LN ;
Cohen, JD ;
Johnson, RB ;
Villarreal, EC ;
Wakulchik, M ;
Loncharich, RJ ;
Wang, QM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (12) :1589-1594
[10]  
KONIG H, 1988, J VIROL, V62, P1243